Skip to Content
Merck

Severe cholestatic jaundice associated with piroxicam.

Gastroenterology (1991-12-01)
K S Hepps, G M Maliha, R Estrada, R W Goodgame
ABSTRACT

A 62-year-old man with rheumatoid arthritis developed jaundice while taking piroxicam. A full evaluation including ultrasound, computerized tomography, endoscopic cholangiography, and liver biopsy confirmed the diagnosis of intrahepatic cholestasis. The patient's jaundice and all other liver function abnormalities normalized 4 months after he discontinued taking piroxicam. This is the first case report in the United States of severe liver toxicity associated with piroxicam. The six cases in the English-language literature are reviewed, featuring the presentation, patterns of liver injury, and outcome in each. Piroxicam should be considered as a potential cause of cholestatic jaundice when other more common etiologies have been excluded.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Piroxicam, meets USP testing specifications
Sigma-Aldrich
Piroxicam, ≥98% (TLC)
Piroxicam for system suitability, European Pharmacopoeia (EP) Reference Standard
Piroxicam, European Pharmacopoeia (EP) Reference Standard
USP
Piroxicam, United States Pharmacopeia (USP) Reference Standard